ArticleUnited European gastroenterology journal2024
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study.
Article in United European gastroenterology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Response to meeting STRIDE-II targets in routine practice: Assessment, access, and service design.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Inflammatory and Immune Cytoprofiles of Active Ulcerative Colitis from Crohn's Disease-Insights from Multivariable Modeling.International journal of molecular sciences · 2026Article
- Endoscopic Bariatric Therapies in Inflammatory Bowel Disease: Patient Selection, Nutritional Risk, and Periprocedural Management.Metabolites · 2026Review
- Treatable traits in inflammatory bowel disease: a conceptual framework for personalized care.EClinicalMedicine · 2026Review
- Real-world data on STRIDE-II treatment targets in a pediatric cohort with inflammatory bowel disease.Journal of pediatric gastroenterology and nutrition · 2026Article
- The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes.Therapeutic advances in gastroenterology · 2026Article
- Positioning Guselkumab in The Treatment Algorithm for Ulcerative Colitis.Journal of inflammation research · 2026Review
- Patterns of conventional therapy use and advanced therapy initiation drivers in inflammatory bowel disease.Therapeutic advances in gastroenterology · 2026Article
- Burden and Trends of Crohn's Disease Among Women of Reproductive Age in China, India, and the United States, 1990-2023, with Projections to 2040: A Systematic Analysis for the Global Burden of Disease Study 2023.International journal of women's health · 2026Article
- Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease-PODCAST Study.United European gastroenterology journal · 2025Article
- IBD-PODCAST Portugal: Proportion of Patients with Suboptimal Disease Control and Its Impact on Quality of Life in Inflammatory Bowel Disease.GE Portuguese journal of gastroenterology · 2025Article
- Beyond the Plate: Patient Perspectives on Diet and Daily Life with Crohn's Disease-A National Survey.Journal of clinical medicine · 2025Article
- Objective Treatment Targets and Their Correlation with Patient-Reported Outcomes in Inflammatory Bowel Disease: A Real-World Study.Journal of clinical medicine · 2025Article
- Structural equation modeling of the impact of disease activity on inflammatory bowel disease control: the mediating roles of self-efficacy and self-management behaviors.BMC gastroenterology · 2025Article
- A Treat-to-Target Approach in IBD: Contemporary Real-World Perspectives from an International Survey.Journal of clinical medicine · 2025Article
- Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn's Disease.Biologics : targets & therapy · 2025Review
- Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study.United European gastroenterology journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCrohn's disease and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) characterized by a progressive nature of the disease resulting in subsequent intestinal damage, limited efficacy of current treatments and suboptimal disease management and a significant burden for patients.
objectivesThe IBD-PODCAST study aims to estimate the proportion of Crohn's disease and UC patients with suboptimal disease control (SDC) in a real-world setting.
methodsA non-interventional and cross-sectional study was conducted across 103 sites in 10 countries (Austria, Belgium, Canada, Germany, Greece, Italy, Portugal, Spain, Turkey, and UK). Criteria for SDC were based on STRIDE-II criteria and adapted by an expert panel.
results2185 patients (Crohn's disease: n = 1,108, UC: n = 1077) with a mean (SD) age of 44.0 (14.8) years and mean (SD) disease duration of 12.4 (9.2) years were included (52.2% male). Ileal involvement was present in 39.1% of Crohn's disease patients, 35.3% of UC patients had extensive colitis. 77.3% of Crohn's disease and 65.3% of UC patients were on targeted immunomodulators and, according to STRIDE-II-based treatment phases, 85.6% of Crohn's disease and 85.4% of UC patients were assigned to the long-term treatment phase. SDC was detected in 52.2% of Crohn's disease and 44.3% of UC patients predominantly due to impaired quality of life (QoL), clinically significant extraintestinal manifestations, steroid overuse, signs of active inflammation in UC and Crohn's disease, and active fistulas in Crohn's disease. More than one criterion was seen in 37% of patients with SDC. Opportunities for on-label treatment optimization were observed in 49% of Crohn's disease and 61% of UC patients on advanced therapy.
conclusionThe high percentage of SDC in this global, real-world cohort suggests a large disease burden and high unmet medical need in IBD patients. Future analysis should focus on monitoring and responding to SDC in this cohort and on patients' QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.